Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oort, Inge van
REDOSE, NCT03927391: Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects	Completed	4	57	Europe	Enzalutamide	Radboud University Medical Center	Prostatic Neoplasms, Castration-Resistant	01/24	01/24
ANZadapt, NCT05393791: Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC	Recruiting	2	168	Europe, RoW	Patient-specific adaptive therapy, Abiraterone acetate, Zytiga, Enzalutamide, Xtandi	Leiden University Medical Center, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Anticancer Fund, Belgium	Prostatic Neoplasms, Castration-Resistant	11/27	11/27
MIND THE GAP, NCT05339672: Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban	Recruiting	N/A	26	Europe	Blood sampling - Pharmacokinetic assessment	Radboud University Medical Center, Astellas Pharma Inc	Drug-drug Interaction	08/24	08/24